Neurocrine Biosciences | NBIX - Market Capitalization


Neurocrine Biosciences reported $17.36B in Market Capitalization this November of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 508.97B 46.71B Nov/2026
Acadia Pharmaceuticals USD 3.57B 100M Nov/2026
Agios Pharmaceuticals USD 1.61B 598M Nov/2026
ALKERMES USD 7.43B 629M Nov/2026
Alnylam Pharmaceuticals USD 33.02B 7.17B Sep/2026
Amgen USD 247.94B 20.06B Nov/2026
Biogen USD 33.38B 1.48B Sep/2026
BioMarin Pharmaceutical USD 10.68B 936M Nov/2026
Cytokinetics USD 7.51B 1.66B Nov/2026
Enanta Pharmaceuticals USD 122M 98M Dec/2024
Exelixis USD 19.82B 5.34B Nov/2026
Gilead Sciences USD 184.82B 27.96B Sep/2026
Halozyme Therapeutics USD 15.62B 3.09B Nov/2026
Incyte USD 24.6B 1.95B Sep/2026
Ionis Pharmaceuticals USD 4.52B 2.9B Nov/2026
Nektar Therapeutics USD 2.12B 1.26B Mar/2026
Neurocrine Biosciences USD 16.38B 1.96B Nov/2026
Pfizer USD 165.12B 1.71B Nov/2026
Prothena USD 437M 76M Nov/2026
Repligen USD 9.74B 1.1B Nov/2026
Sarepta Therapeutics USD 1.65B 276M Nov/2026
Teva Pharmaceutical Industries USD 153.58B 106.85B Nov/2026
Ultragenyx Pharmaceutical USD 1.37B 108M Nov/2026
Vertex Pharmaceuticals USD 140.44B 7.93B Nov/2026